Sensodyne, the toothpaste first marketed in 1961 to reduce the pain of sensitive teeth, is among premium brands on sale in pharmacies and drug stores around the world. But if you live in an Indian ...

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among senior executives at the pharma company to “deliberately slow down&#822… ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his team went through individual scans and interviewed investigators ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

A year after an old tweet caused new problems, pandemic-era posts linked to Pfizer have again been found to have brought discredit on the industry.

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Haleon was formed in 2019 with the merger of GSK and Pfizer's consumer healthcare businesses and later spun out and listed on the London Stock Exchange in 2022.

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.

Pfizer Inc. reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance. “Our overall solid first-quarter performance demonstrates our continued focus on ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the failure of its obesity pill.